Antibodies News and Research

RSS

Study: Iron infusions superior to blood transfusions for surgical patients with anemia

In a rigorous medical records study covering tens of thousands of patients, Johns Hopkins Medicine researchers conclude that some patients with preoperative anemia have better outcomes if they get iron infusions before surgery rather than standard red blood cell transfusions.

25 Jul 2024

Study highlights infection as major post-CAR-T therapy challenge

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.

25 Jul 2024

Oligodendrocytes identified as key amyloid β producers in Alzheimer's disease

Researchers discovered that oligodendrocytes, not just neurons, produce amyloid β in Alzheimer's disease, and suppressing their activity improves disease pathology. This finding suggests new therapeutic targets for Alzheimer's treatment.

24 Jul 2024

Proof-of-concept animal studies demonstrate a step forward in the fight against HIV

Researchers in George Mason University's Center for Infectious Disease Research (CIDR) and Tulane National Primate Research Center conducted a breakthrough proof-of-concept study in Nature's Gene Therapy that found an HIV-like virus particle that could cease the need for lifelong medications.

24 Jul 2024

Reliability of HIV viral load tests for CAB-LA PrEP questioned in new study

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.

23 Jul 2024

Oligodendrocytes identified as key source of amyloid beta in Alzheimer's disease

Oligodendrocytes are an important source of amyloid beta (Aβ) and play a key role in promoting neuronal dysfunction in Alzheimer's disease (AD), according to a study published July 23, 2024 in the open-access journal PLOS Biology by Rikesh Rajani and Marc Aurel Busche from the UK Dementia Research Institute at University College London, and colleagues.

23 Jul 2024

Evaluation and treatment of early Lyme disease

Every year in the United States, an estimated 476,000 people are diagnosed and treated for Lyme disease. The estimate comes from the U.S. Centers for Disease Control and Prevention (CDC).

23 Jul 2024

PrEPVacc HIV vaccine trial shows no reduction in infections

The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.

23 Jul 2024

USC scientists transform B cells into cancer and HIV destroyers

USC scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy cancer cells or HIV, two of medicine's most formidable foes.

22 Jul 2024

Breakthrough malaria vaccines RTS,S and R21 poised to save thousands of lives

Research paper reviews the efficacy of the first licensed malaria vaccines, RTS,S and R21, highlighting their potential to significantly reduce childhood mortality and discussing future vaccine development strategies.

21 Jul 2024

Long-term immune changes persist in unvaccinated COVID-19 patients

Study reveals that unvaccinated individuals experience significant long-term changes in immune parameters up to ten months post-COVID-19 infection, with a shift towards a Th2 cytokine profile.

21 Jul 2024

AI and imaging advances revolutionize multiple sclerosis diagnosis

A study in Translational Vision Science & Technology reveals that integrating AI with IR-SLO and OCT imaging improves the automated diagnosis and classification of multiple sclerosis.

21 Jul 2024

High mutation count in new COVID-19 variants does not increase immune evasion, study finds

New research from UNC Charlotte's Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two recent and prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to Omicron.

19 Jul 2024